Latest Tax Incentives News

Rewardle Holdings addresses ASX queries on its CloudHolter investment, convertible note funding, and financial restatements, while outlining its going concern status despite operational losses.

Arovella Therapeutics has received a $3.21 million R&D tax incentive refund, bolstering its financial position as it prepares to initiate first-in-human trials for its lead cell therapy, ALA-101.

Noxopharm Limited has secured an extension on $2.6 million of convertible notes and obtained a $1.25 million unsecured loan to bolster working capital, pending shareholder approval.

ChemX Materials Limited has entered voluntary administration following a turbulent quarter marked by convertible note amendments, a trading suspension, and ongoing funding challenges.

Neurizon Therapeutics has locked in a significant R&D tax incentive advance covering overseas and domestic development costs for its lead ALS drug candidate NUZ-001, accelerating its clinical progress with a $5.6 million rebate expected in 2025.

CloudHolter Pty Ltd reported a substantial $39.7 million net loss for FY2025 amid ongoing cash outflows but continues to raise capital through convertible notes as it targets an IPO by year-end.

Kingsgate Consolidated reports a strong FY25 at its Chatree Gold Mine with 75,000 ounces produced and sets ambitious FY26 targets, while advancing its Chilean project.

Metals Australia Ltd reports key milestones in its Lac Carheil Graphite Project, achieving battery-grade spherical graphite purity and selecting Sept-Îles as the preferred site for its Battery Anode Material plant.

Euro Manganese Inc. reports significant progress on its Chvaletice Project and Bécancour Plant, positioning itself as a key Western supplier of high-purity manganese critical for EV batteries. The company highlights strong feasibility results, strategic financing partnerships, and multiple offtake agreements amid an expected global supply deficit.

SenSen Networks has secured $2 million in new contracts across Singapore, the USA, and Australia, reinforcing its position as a leader in Live Awareness AI solutions. The company also strengthened its balance sheet with $1.5 million cash received from a recent Montreal project.

ALCORE, ABx Group’s subsidiary, has secured government approval for overseas R&D activities and is pursuing a $5 million grant to accelerate its clean fluorine chemical technology commercialisation.

Acrux Limited has received a $3.04 million R&D Tax Incentive rebate for FY25 and fully repaid its short-term funding facility, underscoring its commitment to Australian pharmaceutical innovation.